Androgenic Therapy for Advanced Breast Cancer in Women

Goldenberg, Ira S.; Waters, M. Nancy; Ravdin, Robert S.; Ansfield, Fred J.; Segaloff, Albert

doi:10.1001/jama.1973.03220110045012

Cited by 59 publications

(12 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has been previously suggested by demonstration of clinical responses to testololactone (Goldenberg et al, 1973) and aminoglutethimide (Santen et al, 1981) and recently confirmed by the demonstration of Right-hand column-breast cancer patients on AG:…”

Section: Discussionsupporting

confidence: 55%

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients

Dowsett¹,

Santner²,

Santen³

et al. 1985

Br J Cancer

View full text Add to dashboard Cite

Aminoglutethimide without glucocorticoid has been shown to be a clinically effective treatment for postmenopausal breast cancer in low dosage (250 mg day-1). The mechanism of action of this approach is thought to be the inhibition of peripheral aromatase, the enzyme which converts androstenedione to oestrone. The activity of this enzyme was measured in vivo by injection with 3H-androstenedione and 14C-oestrone and found to be 0.20% +/- 0.05 in 5 patients on low dose AG therapy. In comparison with previously published data this demonstrates a 92% inhibition of peripheral aromatase activity confirming aromatase inhibition as a viable aim in the endocrine treatment of breast cancer.

show abstract

Section: Discussionsupporting

confidence: 55%

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients

Dowsett¹,

Santner²,

Santen³

et al. 1985

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In female patients, this compound showed antitumor efficacy in both pre and post menopausal women with local, visceral, or osseous metastases [1,2,3]. Knowing that antitumor acti vity does not depend on an androgenic effect [2] we decided to try calusterone in males.…”

Section: Discussionmentioning

confidence: 99%

“…Calusterone (7a, 17p dimethyl testosterone, Methosarb® Upjohn), a synthetic testosterone molecule with slight viriliz ing activity has produced remissions in half the female pa tients studied with duration of remission averaging a year but in some instances continuing for four years [1,2,3], In two male patients with breast cancer who had progression of mea surable lesions in lungs and/or bones, after a long period of quiescent disease following orchiectomy and mastectomy, hor monal manipulation was instituted using calusterone. A remis sion in measurable disease in both patients resulted and in one patient reversion of hypercalcemia to normocalcemia occurred with therapy.…”

Section: Introductionmentioning

confidence: 99%

Male Breast Cancer: Two Cases with Objective Regressions from Calusterone (7α, 17β-dimethyltestosterone) after Failure of Orchiectomy

Horn

Roof²

1976

Oncology

View full text Add to dashboard Cite

Calusterone (7α, 17β-dimethyltestosterone) is an orally effective weakly androgenic steroid. The antitumor efficacy of calusterone, 200 mg per day against objectively progressing advanced breast cancer in females has already been reported. In the present study calusterone was used in metastatic breast cancer in. two male patients. Both had failed to continue respond to orchiectomy and had measurable lesions one in the lungs, the other in the bones. Both patients showed objective regression (blastic response of osteolytic lesions and disappearance of lung metastases) lasting five months in one patient and more than seven months in the other, who is still in regression. Further experience is necessary for statistically adequate results.

show abstract

“…A change in values will necessarily be reflected in the acquisition of more power by groups that presently possess small amounts of it, which in turn will imply organizing these groups so that they achieve greater participation and self-determination. In other words, they must aquire the feeling that they can decide what will happen to them (Goldenberg, 1973;Reiff, 1968). This process will bring about a change in the ideology of an individual, group, organization, or institution-community that will alter the distribution of power within it (Cheder & Worden, 1974; Crowfoot & Cheder, 1974).…”

Section: Form Function and Intervention Levelsmentioning

confidence: 99%

Toward a social-community psychology

Serrano‐García

López

Rivera-Medina

1987

J. Community Psychol.

View full text Add to dashboard Cite

This article presents a conceptual framework for social‐community psychology that is the basis of a master's‐level training program with the same name at the University of Puerto Rico. The framework responds to the crisis of confidence in social psychology and to the selection of a social change emphasis for community psychology. Its theoretical basis and its practical applications are explained.

show abstract

Androgenic Therapy for Advanced Breast Cancer in Women

Cited by 59 publications

References 2 publications

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients

Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients

Male Breast Cancer: Two Cases with Objective Regressions from Calusterone (7α, 17β-dimethyltestosterone) after Failure of Orchiectomy

Toward a social-community psychology

Contact Info

Product

Resources

About